Drug intelligence / Profile preview

MBT-002

Development stage: Preclinical
Lead developer: MVRIX
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular, Intradermal

Overview

MBT-002 is a next-generation recombinant botulinum toxin candidate developed by MVRIX. Produced using an E. coli-based recombinant protein engineering platform, it is designed to modulate the botulinum toxin receptor and the deubiquitinase pathway. The drug is intended for both aesthetic (cosmetic) and therapeutic neuromuscular indications. MBT-002 is engineered to offer improvements over traditional botulinum toxin formulations, specifically targeting faster onset of action, extended duration of effect, and an enhanced safety profile. It is currently in preclinical development.

Other names: recombinant botulinum toxin

Targets

SV2A (Synaptic vesicle glycoprotein 2A)DUB (Deubiquitinases)

Beyond the preview

Go deeper on MBT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBT-002.

Explore the full profile